Abiomed Forecasts Recover Micropump U.S. Approval In 2006
This article was originally published in The Gray Sheet
Executive Summary
Abiomed expects profitability in 2007 following U.S. approval of Recover 5.0 and 2.5 second-generation micropumps, which it acquired from Impella CardioSystems AG in April
You may also be interested in...
Abiomed Submits 510(k) For Impella Ventricular Assist Device
Abiomed hopes to gain FDA market clearance of its Impella 2.5 minimally invasive ventricular assist device later this year following the firm's recent 510(k) submission, announced Feb. 5
Abiomed Submits 510(k) For Impella Ventricular Assist Device
Abiomed hopes to gain FDA market clearance of its Impella 2.5 minimally invasive ventricular assist device later this year following the firm's recent 510(k) submission, announced Feb. 5
Abiomed Readies New Products In Wake Of Negative FDA Panel Vote
Abiomed has commitments from several major clinical centers to conduct trials for its Recover 2.5 and 5.0 second-generation cardiac micropumps, following investigational device exemption submissions to FDA